Rechallenge for Patients With RAS and BRAF Wild-Type Metastatic Colorectal Cancer With Acquired Resistance to First-line Cetuximab and Irinotecan: A Phase 2 Single-Arm Clinical Trial

IMPORTANCE: Based on a small retrospective study, rechallenge with cetuximab-based therapy for patients with KRAS wild-type metastatic colorectal cancer (mCRC) who were previously treated with the same anti–epidermal growth factor receptor–based regimen might be efficacious. Recent data suggest the...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:JAMA Oncol
Autors principals: Cremolini, Chiara, Rossini, Daniele, Dell’Aquila, Emanuela, Lonardi, Sara, Conca, Elena, Del Re, Marzia, Busico, Adele, Pietrantonio, Filippo, Danesi, Romano, Aprile, Giuseppe, Tamburini, Emiliano, Barone, Carlo, Masi, Gianluca, Pantano, Francesco, Pucci, Francesca, Corsi, Domenico C., Pella, Nicoletta, Bergamo, Francesca, Rofi, Eleonora, Barbara, Cecilia, Falcone, Alfredo, Santini, Daniele
Format: Artigo
Idioma:Inglês
Publicat: American Medical Association 2018
Matèries:
Original Investigation
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6439839/
https://ncbi.nlm.nih.gov/pubmed/30476968
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2018.5080
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars